Johana Álvarez-Jiménez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Johana Álvarez-Jiménez has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Blanca Acha
Neuroepigenetics Unit, Navarrabiomed, Universidad Pública de Navarra, IdiSNA, Pamplona, Spain
2 shared publications - Eneko Cabezon-Arteta
Neuroepigenetics Unit, Navarrabiomed, Universidad Pública de Navarra, IdiSNA, Pamplona, Spain
2 shared publications - Idoia Blanco-Luquin
Neuroepigenetics Unit, Navarrabiomed, Universidad Pública de Navarra, IdiSNA, Pamplona, Spain
2 shared publications - Maite Mendioroz
Neuroepigenetics Unit-Navarrabiomed, University Hospital of Navarra, Universidad Pública de Navarra, Navarra Institute for Health Research (IdiSNA)
2 shared publications - Miren Roldan
Neuroepigenetics Unit, Navarrabiomed, Universidad Pública de Navarra, IdiSNA, Pamplona, Spain
2 shared publications - Mónica Macías
Neuroepigenetics Unit-Navarrabiomed, University Hospital of Navarra, Universidad Pública de Navarra, Navarra Institute for Health Research (IdiSNA)
2 shared publications
Latest Publications
- Open Access
- 27 May 2026
- Published by Springer Nature in Mindfulness
- Vol. 17 (9) , 1-11
Dynamic Methylation Changes in Alzheimer’s Disease-Related Genes During Mindfulness Practice – a Proof-of-Concept Study
- 27 May 2026
- Published by Springer Nature in Mindfulness
- Vol. 17 (9) , 1-11
Open AccessDynamic Methylation Changes in Alzheimer’s Disease-Related Genes During Mindfulness Practice – a Proof-of-Concept Study
- Open Access
- 5 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3419
Advancing Personalized Medicine in Alzheimer’s Disease: Liquid Biopsy Epigenomics Unveil APOE ε4-Linked Methylation Signatures
Recent studies show that patients with Alzheimer’s disease (AD) harbor specific methylation marks in the brain that, if accessible, could be used as epigenetic biomarkers. Liquid biopsy enables the study of circulating cell-free DNA (cfDNA) fragments originated from dead cells, including neurons affected by neurodegenerative processes. Here, we isolated and epigenetically characterized plasma cfDNA from 35 patients with AD and 35 cognitively healthy controls by using the Infinium® MethylationEPIC BeadChip array. Bioinformatics analysis was performed to identify differential methylation positions (DMPs) and regions (DMRs), including APOE ε4 genotype stratified analysis. Plasma pTau181 (Simoa) and cerebrospinal fluid (CSF) core biomarkers (Fujirebio) were also measured and correlated with differential methylation marks. Validation was performed with bisulfite pyrosequencing and bisulfite cloning sequencing. Epigenome-wide cfDNA analysis identified 102 DMPs associated with AD status. Most DMPs correlated with clinical cognitive and functional tests including 60% for Mini-Mental State Examination (MMSE) and 80% for Global Deterioration Scale (GDS), and with AD blood and CSF biomarkers. In silico functional analysis connected 30 DMPs to neurological processes, identifying key regulators such as SPTBN4 and APOE genes. Several DMRs were annotated to genes previously reported to harbor epigenetic brain changes in AD (HKR1, ZNF154, HOXA5, TRIM40, ATG16L2, ADAMST2) and were linked to APOE ε4 genotypes. Notably, a DMR in the HKR1 gene, previously shown to be hypermethylated in the AD hippocampus, was validated in cfDNA from an orthogonal perspective. These results support the feasibility of studying cfDNA to identify potential epigenetic biomarkers in AD. Thus, liquid biopsy could improve non-invasive AD diagnosis and aid personalized medicine by detecting epigenetic brain markers in blood.
- 5 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3419
Open AccessAdvancing Personalized Medicine in Alzheimer’s Disease: Liquid Biopsy Epigenomics Unveil APOE ε4-Linked Methylation Signatures
Recent studies show that patients with Alzheimer’s disease (AD) harbor specific methylation marks in the brain that, if accessible, could be used as epigenetic biomarkers. Liquid biopsy enables the study of circulating cell-free DNA (cfDNA) fragments originated from dead cells, including neurons affected by neurodegenerative processes. Here, we isolated and epigenetically characterized plasma cfDNA from 35 patients with AD and 35 cognitively healthy controls by using the Infinium® MethylationEPIC BeadChip array. Bioinformatics analysis was performed to identify differential methylation positions (DMPs) and regions (DMRs), including APOE ε4 genotype stratified analysis. Plasma pTau181 (Simoa) and cerebrospinal fluid (CSF) core biomarkers (Fujirebio) were also measured and correlated with differential methylation marks. Validation was performed with bisulfite pyrosequencing and bisulfite cloning sequencing. Epigenome-wide cfDNA analysis identified 102 DMPs associated with AD status. Most DMPs correlated with clinical cognitive and functional tests including 60% for Mini-Mental State Examination (MMSE) and 80% for Global Deterioration Scale (GDS), and with AD blood and CSF biomarkers. In silico functional analysis connected 30 DMPs to neurological processes, identifying key regulators such as SPTBN4 and APOE genes. Several DMRs were annotated to genes previously reported to harbor epigenetic brain changes in AD (HKR1, ZNF154, HOXA5, TRIM40, ATG16L2, ADAMST2) and were linked to APOE ε4 genotypes. Notably, a DMR in the HKR1 gene, previously shown to be hypermethylated in the AD hippocampus, was validated in cfDNA from an orthogonal perspective. These results support the feasibility of studying cfDNA to identify potential epigenetic biomarkers in AD. Thus, liquid biopsy could improve non-invasive AD diagnosis and aid personalized medicine by detecting epigenetic brain markers in blood.